Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

A decision is expected in the fourth quarter of 2025.

But so far, most researchers are reassured as are regulators in the UK, United States and Europe.”Prof Sattar and Dr Cork have unpacked the side effects to be aware of:BlindnessStomach issues‘Ozempic ...

The chart below compares the cost of an annualized semaglutide dosage from Hims, versus competitors: The pivot to liraglutide will allow Hims & Hers to prolong its operations in the weight-loss ...

Ozempic (semaglutide) and Wegovy (semaglutide ... Learn how Wegovy is used for weight loss. How do dosage and administration compare for Ozempic and Wegovy? The following table highlights the ...

BioPharmaDive notes that the pill Novo wants FDA approval for contains 70 times as much semaglutide as injectable Ozempic. The journal points out that such a large increase in dosage will require ...